Bipolar Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis between BD and T2D identified six significant SNPs, three of which were located in ALAS1 (best SNP: rs352165, p = 3.4E-08).
|
31754094 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis between BD and T2D identified six significant SNPs, three of which were located in ALAS1 (best SNP: rs352165, p = 3.4E-08).
|
31754094 |
2019 |
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In contrast, protein and mRNA levels of heme synthesis rate limiting enzyme aminolevulinic acid synthase-1 (ALAS1) were unchanged in SZ derived LCLs.
|
30948194 |
2019 |
Hereditary Coproporphyria
|
0.010 |
Biomarker
|
disease |
BEFREE |
To introduce next generation sequencing (NGS) to the porphyria diagnosis, we designed a panel that contained four genes, <i>ALAS1, HMBS</i>, <i>CPOX</i> and <i>PPOX</i> for mutational analysis of acute intermittent porphyria (AIP), hereditary coproporphyria (HCP) and variegate porphyria (VP).
|
31154864 |
2019 |
Variegate Porphyria
|
0.010 |
Biomarker
|
disease |
BEFREE |
To introduce next generation sequencing (NGS) to the porphyria diagnosis, we designed a panel that contained four genes, <i>ALAS1, HMBS</i>, <i>CPOX</i> and <i>PPOX</i> for mutational analysis of acute intermittent porphyria (AIP), hereditary coproporphyria (HCP) and variegate porphyria (VP).
|
31154864 |
2019 |
Neurologic Symptoms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Acute porphyric attacks, precipitated by fasting, certain hormones and some drugs, involve induction of 5-ALAS secondarily to depletion of the above pool, and the resultant elevation of 5-ALA levels initiates the abdominal and neurological symptoms of attacks.
|
31443750 |
2019 |
Hepatitis C
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis showed a higher expression level of FLVCR1, but not ABCG2, as well as a higher expression level of mature ALAS1, which is the rate-limiting enzyme in the heme synthesis pathway, in HCV core protein-expressing cells compared with controls.
|
29856826 |
2018 |
Impaired glucose tolerance
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Mice heterozygous null for ALAS1 (A1+/-s) experience impaired glucose tolerance (IGT) and insulin resistance (IR) beyond 20-weeks of age (aged A1+/-s).
|
29364890 |
2018 |
Porphyria, Erythropoietic
|
0.010 |
Biomarker
|
disease |
BEFREE |
The treatment of hepatic porphyrias by an RNAi-targeting hepatic ALAS1 is actually tested and may lead to improve the management of acute attacks.In erythropoietic porphyrias, the key role of ALAS2 as a gate keeper of the heme and subsequently hemoglobin synthesis has been demonstrated.
|
28118224 |
2017 |
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
The validation experiment (geNorm) showed that the most stable gene combinations were ALAS1 and GAPDH in NFPA, and PSMC4 and GAPDH in hormone secreting adenomas.
|
27561203 |
2016 |
Diabetes
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the expression of ALAS1 in a murine model of diabetes and determined the effects of the insulinomimetic vanadate on the enzyme regulation to evaluate its potential for the treatment of acute porphyria attacks.
|
22070747 |
2012 |
Diabetes Mellitus
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We evaluated the expression of ALAS1 in a murine model of diabetes and determined the effects of the insulinomimetic vanadate on the enzyme regulation to evaluate its potential for the treatment of acute porphyria attacks.
|
22070747 |
2012 |
Neuropsychiatric syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Acute porphyrias are characterized by a neuropsychiatric syndrome with intermittent induction of hepatic ALAS1 (δ-aminolaevulinate synthase 1), the first and rate-limiting enzyme of the haem pathway.
|
22070747 |
2012 |
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
We recommend using KALPHA-TBP for the study of T1T2 tumors, RPL27-SHAD for T3T4 tumors, KALPHA-SHAD for N0 tumors, and ALAS-TBP for N+ tumors.
|
19650912 |
2009 |
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
The use of HPRT1 alone as a reference gene shown in our study was sufficient, but the normalization factors generated from two (HRPT1, ALAS1) or all three genes (HRPT1, ALAS1, K-ALPHA-1) should be considered for an improved reliability of normalization in gene profiling studies of prostate cancer.
|
16211407 |
2005 |
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The use of HPRT1 alone as a reference gene shown in our study was sufficient, but the normalization factors generated from two (HRPT1, ALAS1) or all three genes (HRPT1, ALAS1, K-ALPHA-1) should be considered for an improved reliability of normalization in gene profiling studies of prostate cancer.
|
16211407 |
2005 |
Liver Failure, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we examined expression of HO-1 as well as the non-specific delta-aminolevulinate synthase (ALAS-N, or ALAS1), the rate-limiting enzyme in heme catabolism and biosynthesis, respectively, in the livers of patients with ALF.
|
15547665 |
2004 |
Liver Failure, Acute
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
These findings suggest that, in the liver of ALF patients, there may be an increase in free heme concentration which up-regulates HO-1 gene expression, while down-regulating ALAS1 gene expression, resulting in markedly altered heme metabolism and liver function.
|
15547665 |
2004 |
MELORHEOSTOSIS, ISOLATED
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mouse erythroleukemia (MEL) cells transformed by Friend virus and induced to undergo erythroid differentiation by treatment with hexamethylenebisacetamide (HMBA) increase erythroid specific 5-aminolevulinate synthase (ALAS-E) mRNA levels by 4-15-fold and decrease "housekeeping" 5-aminolevulinate synthase (ALAS-N) mRNA levels by 1.2-1.4-fold.
|
8843957 |
1996 |
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We found that the expression levels of the rate-limiting heme synthetic enzyme ALAS1 and heme degradation enzyme HO-2 are selectively decreased in AD patients and mice.
|
30723777 |
2019 |
Sideroblastic anemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In patients, ALAS enzyme activity is affected in most of the mutations causing non-syndromic SA and in several porphyrias.
|
30737140 |
2019 |
Erythropoietic Protoporphyria
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Moreover, ALAS2 gain of function mutations is responsible for X-linked protoporphyria and increased ALAS1 activity lead to acute attacks of hepatic porphyrias.
|
30737140 |
2019 |
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The relative expression of ALAS1 mRNA, the first and rate-limiting enzyme for heme biosynthesis under normal physiological conditions, was significantly (p<0.05) reduced by nearly 90% in AD compared to control.
|
19477221 |
2009 |
Erythropoietic Protoporphyria
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In about 2% of patients, overt disease was recently shown to be caused by gain-of-function mutations in the erythroid-specific aminolevulinic acid synthase 2 (ALAS2/ALAS, EC 2.3.1.27) gene and named X-linked dominant protoporphyria.
|
19744342 |
2009 |
Sideroblastic anemia
|
0.020 |
GeneticVariation
|
disease |
LHGDN |
Multiple mechanisms for hereditary sideroblastic anemia.
|
11929048 |
2002 |